Capricor Therapeutics Inc (CAPR)

Price$28.53

Value ScoreF

Growth ScoreC

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)410.61%

Price vs S&P 500 (4W)-8.05%

VGM Score48.05

Market Capitalization$1.74B

All Metrics

Book Value / Share (Quarterly)$4.83

P/TBV (Annual)2.26x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)352.73%

Cash Flow / Share (Quarterly)$-1.98

Price vs S&P 500 (YTD)-7.12%

Net Profit Margin (TTM)-181.71%

EPS (TTM)$-2.31

10-Day Avg Trading Volume0.81M

EPS Excl Extra (TTM)$-2.31

Revenue Growth (5Y)85.64%

EPS (Annual)$-2.26

ROI (Annual)-33.64%

Net Profit Margin (5Y Avg)-2831.28%

Cash / Share (Quarterly)$4.83

ROA (Last FY)-29.51%

Revenue Growth TTM (YoY)-52.08%

EBITD / Share (TTM)$-2.39

ROE (5Y Avg)-94.15%

Operating Margin (TTM)-191.13%

Cash Flow / Share (Annual)$-1.42

P/B Ratio6.23x

P/B Ratio (Quarterly)6.27x

Net Income / Employee (Annual)$-454,700

EV / Revenue (TTM)73.46x

Net Interest Coverage (TTM)7.75x

ROA (TTM)-48.65%

EV / EBITDA (TTM)3338.69x

EPS Incl Extra (Annual)$-2.26

Current Ratio (Annual)9.01x

Quick Ratio (Quarterly)8.28x

3-Month Avg Trading Volume1.20M

52-Week Price Return196.93%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$1.30

P/S Ratio (Annual)77.91x

Asset Turnover (Annual)0.13x

52-Week High$40.37

Operating Margin (5Y Avg)-2891.85%

EPS Excl Extra (Annual)$-2.26

CapEx CAGR (5Y)84.39%

Tangible BV CAGR (5Y)46.12%

26-Week Price Return426.54%

Quick Ratio (Annual)8.88x

13-Week Price Return7.42%

Total Debt / Equity (Annual)0.02x

Current Ratio (Quarterly)8.42x

Enterprise Value$1.64B

Revenue / Share Growth (5Y)18.36%

Asset Turnover (TTM)0.25x

Book Value / Share Growth (5Y)31.22%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-181.71%

Cash / Share (Annual)$5.55

3-Month Return Std Dev69.83%

Net Income / Employee (TTM)$-496,100

ROE (Last FY)-34.35%

Net Interest Coverage (Annual)-28.45x

EPS Basic Excl Extra (Annual)$-2.26

P/FCF (TTM)461.45x

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.02x

EPS Incl Extra (TTM)$-2.31

Receivables Turnover (Annual)0.00x

ROI (TTM)-57.81%

P/S Ratio (TTM)77.91x

Pretax Margin (5Y Avg)-2831.28%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$1.30

Forward P/E212.64x

Price vs S&P 500 (52W)168.72%

Year-to-Date Return3.81%

5-Day Price Return3.78%

EPS Normalized (Annual)$-2.26

ROA (5Y Avg)-39.52%

Net Profit Margin (Annual)-181.71%

Month-to-Date Return-10.78%

Cash Flow / Share (TTM)$-1.11

EBITD / Share (Annual)$-2.29

Operating Margin (Annual)-191.13%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-79.11%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-2.31

P/TBV (Quarterly)2.26x

P/B Ratio (Annual)5.13x

Pretax Margin (TTM)-181.71%

Book Value / Share (Annual)$5.33

Price vs S&P 500 (13W)-2.32%

Beta0.26x

P/FCF (Annual)1112.21x

Revenue / Share (TTM)$0.00

ROE (TTM)-59.27%

52-Week Low$4.30

vGradeF

gGradeC

mGradeB

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.59est. -0.54

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.19

4.13

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
CAPRCapricor Therapeutics Inc	F	C	B	$28.53
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
ABTAbbott Laboratories	C	C	D	$87.78
PFEPfizer Inc.	B	C	C	$25.63
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Capricor Therapeutics is a clinical-stage biotechnology company developing cell and exosome-based therapies for rare diseases with high unmet medical needs. Its lead candidate, deramiocel (an allogeneic cardiac-derived cell therapy), is in Phase 3 clinical development for Duchenne muscular dystrophy. The company's proprietary StealthX platform supports preclinical research in vaccine delivery and targeted molecular therapeutics.